Authors: Oana Manea1, Cristina Bidian2, Remus Moldovan2, Tudor-Valentin Mîrza3, Floris Petru Iliuță4, Mihnea Costin Manea4, Adela Magdalena Ciobanu5
1Carol Davila University of Medicine and Pharmacy, PhD student, Bucharest, Romania
2“Iuliu Haţieganu” University of Medicine and Pharmacy, Faculty of Medicine, Department of Physiology, Cluj-Napoca, Romania
3National Institute of Public Health – Regional Center of Public Health, Cluj-Napoca, Romania
4Carol Davila University of Medicine and Pharmacy, Faculty of Dental Medicine, Discipline of Psychiatry and Psychology, Prof Dr. Al. Obregia Clinical Hospital, Bucharest, Romania
5Carol Davila University of Medicine and Pharmacy, Faculty of Medicine, Discipline of Psychiatry, Prof Dr. Al. Obregia Clinical Hospital Bucharest, Romania
Background. The use of atypical antipsychotics to increase the antidepressant pharmacological treatment in the experimental depressive disorder was analyzed.
Aims. We aimed to study experimentally, on a model of rat-induced depression, the effects of an atypical antipsychotic (Quetiapine) and major antidepressant (Agomelatine), associated with Omega-3 polyunsaturated fatty acids, on emotional and locomotor behavior and motor learning.
Methods. The animals were assigned to five groups as follows: G I – control animals; G II – animals with reserpine-induced depression; G III – animals with reserpine-induced depression, treated with Quetiapine; G IV – animals with reserpine-induced depression and treated with Quetiapine and Agomelatine; G V – animals with reserpine-induced depression, treated with Quetiapine, Agomelatine and supplemented with Omega-3 fatty acids, in which emotional and locomotor behavior were tested by the open field test, whereas motor and memory learning were tested by the Morris Water Maze Test.
Results. Thirty days later, the treatment with Quetiapine caused, in sedentary animals with reserpine-induced experimental depression, a decrease in excitability, involuntary mobility, in the learning ability and control, compared to control animals with depression. The co-treatment with Quetiapine and Agomelatine (a major antidepressant) in sedentary animals with reserpine-induced depression decreased excitability, increased involuntary mobility, learning ability, and its control after 30 days, compared to control animals with depression and those treated with Quetiapine. The co-treatment with Quetiapine, Agomelatine, and Omega-3 fatty acids supplements of sedentary animals with reserpine-induced depression caused a decrease in excitability and an increase in involuntary motility after 30 days, and an increase in the learning ability, decreasing its control over the group not supplemented with Omega-3 fatty acids.
Conclusions. The therapeutic combination used – antipsychotic and antidepressant, with and without the addition of Omega-3 fatty acids, has favorable neurobehavioral effects in experimental depression.
Key words: depression, Reserpine, Quetiapine, Agomelatine, Omega-3 fatty acids, open field test, Morris test